URGN Similar Chart Price Prediction
The price of URGN is predicted to go up 2.78%, based on the high correlation periods with BFK. The similarity of these two price pattern on the periods is 91.33%.
URGN
BFK
Up: 2.78%Similarity: 91.33%
URGN Revenue Forecast
URGN EPS Forecast
URGN FAQs
What is bull’s view on URGN?
What is bear's view on URGN?
What is URGN revenue forecast for next quarter？
What is URGN eps forecast for next quarter？
URGN Analyst's Forecast
Jason Kolbert
D. Boral Capital
Strong Buy
2025-02-20
Price Target
$25
Upside
+133.43%
UroGen Pharma announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in development for treatment of LG-IR-NMIBC. Analyses of pre-specified subgroups showed comparable CR rates and DOR patterns across different levels of tumor burden and number of tumors at baseline in patients treated with UGN-102. The poster presentation titled, Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of the Phase 3 ENVISION Trial was presented today at ASCO GU 2025. "We are encouraged by these results, which highlight the potential of UGN-102 to provide durable responses in patients with recurrent LG-IR-NMIBC," said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. "These pre-specified subgroup analyses further strengthen the growing body of evidence supporting UGN-102 as a treatment option for patients dealing with the challenges of disease recurrence and the need for repeated surgeries."
Jason Kolbert
EF Hutton
Strong Buy
2024-10-14
Price Target
$25
Upside
+103.92%
